Literature DB >> 25247369

Focusing brain therapeutic interventions in space and time for Parkinson's disease.

S Little1, P Brown2.   

Abstract

The last decade has seen major progress at all levels of neuroscience, from genes and molecules up to integrated systems-level models of brain function. In particular, there have been advances in the understanding of cell-type-specific contributions to function, together with a clearer account of how these contributions are coordinated from moment to moment to organise behavior. A major current endeavor is to leverage this knowledge to develop new therapeutic approaches. In Parkinson's disease, there are a number of promising emerging treatments. Here, we will highlight three ambitious novel therapeutic approaches for this condition, each robustly driven by primary neuroscience. Pharmacogenetics genetically re-engineers neurons to produce neurotrophins that are neuroprotective to vulnerable dopaminergic cells or to directly replace dopamine through enzyme transduction. Deep brain stimulation (DBS) is undergoing a transformation, with adaptive DBS controlled by neural signals resulting in better motor outcomes and significant reductions in overall stimulation that could reduce side effects. Finally, optogenetics presents the opportunity to achieve cell-type-specific control with a high temporal specification on a large enough scale to effectively repair network-level dysfunction.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25247369      PMCID: PMC4813760          DOI: 10.1016/j.cub.2014.08.002

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  100 in total

1.  Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

Authors:  Piotr Hadaczek; Jamie L Eberling; Philip Pivirotto; John Bringas; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  Optogenetics in neural systems.

Authors:  Ofer Yizhar; Lief E Fenno; Thomas J Davidson; Murtaza Mogri; Karl Deisseroth
Journal:  Neuron       Date:  2011-07-14       Impact factor: 17.173

3.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

Review 4.  Optogenetic insights into striatal function and behavior.

Authors:  Jeffrey D Lenz; Mary Kay Lobo
Journal:  Behav Brain Res       Date:  2013-04-28       Impact factor: 3.332

Review 5.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

6.  Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

Authors:  Béchir Jarraya; Sabrina Boulet; G Scott Ralph; Caroline Jan; Gilles Bonvento; Mimoun Azzouz; James E Miskin; Masahiro Shin; Thierry Delzescaux; Xavier Drouot; Anne-Sophie Hérard; Denise M Day; Emmanuel Brouillet; Susan M Kingsman; Philippe Hantraye; Kyriacos A Mitrophanous; Nicholas D Mazarakis; Stéphane Palfi
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

7.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.

Authors:  H Bergman; T Wichmann; M R DeLong
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

8.  Responsive cortical stimulation for the treatment of medically intractable partial epilepsy.

Authors:  Martha J Morrell
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

Review 9.  Parkinson's disease: from monogenic forms to genetic susceptibility factors.

Authors:  Suzanne Lesage; Alexis Brice
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

10.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.

Authors:  H Bergman; T Wichmann; B Karmon; M R DeLong
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

View more
  12 in total

1.  Agency and intervention.

Authors:  Adina L Roskies
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

2.  Neuroscience: spotlight on deep-brain stimulation.

Authors:  Alim Louis Benabid
Journal:  Nature       Date:  2015-03-19       Impact factor: 49.962

3.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

4.  Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Authors:  Amy W Amara; Harrison C Walker; Allen Joop; Gary Cutter; Jennifer L DeWolfe; Susan M Harding; David G Standaert
Journal:  Mov Disord Clin Pract       Date:  2016-06-06

5.  Optogenetic stimulation of glutamatergic neuronal activity in the striatum enhances neurogenesis in the subventricular zone of normal and stroke mice.

Authors:  Mingke Song; Shan Ping Yu; Osama Mohamad; Wenyuan Cao; Zheng Zachory Wei; Xiaohuan Gu; Michael Qize Jiang; Ling Wei
Journal:  Neurobiol Dis       Date:  2016-11-21       Impact factor: 5.996

6.  Mechanisms regulating spill-over of synaptic glutamate to extrasynaptic NMDA receptors in mouse substantia nigra dopaminergic neurons.

Authors:  A R Wild; M Bollands; P G Morris; S Jones
Journal:  Eur J Neurosci       Date:  2015-10-20       Impact factor: 3.386

Review 7.  New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.

Authors:  Huamin Xu; Hong Jiang; Junxia Xie
Journal:  Front Mol Neurosci       Date:  2017-03-16       Impact factor: 5.639

8.  Spatio-temporal dynamics of cortical drive to human subthalamic nucleus neurons in Parkinson's disease.

Authors:  Andrew Sharott; Alessandro Gulberti; Wolfgang Hamel; Johannes A Köppen; Alexander Münchau; Carsten Buhmann; Monika Pötter-Nerger; Manfred Westphal; Christian Gerloff; Christian K E Moll; Andreas K Engel
Journal:  Neurobiol Dis       Date:  2018-01-04       Impact factor: 5.996

9.  Myopic control of neural dynamics.

Authors:  David Hocker; Il Memming Park
Journal:  PLoS Comput Biol       Date:  2019-03-11       Impact factor: 4.779

10.  Phase-dependent modulation as a novel approach for therapeutic brain stimulation.

Authors:  Ramin Azodi-Avval; Alireza Gharabaghi
Journal:  Front Comput Neurosci       Date:  2015-02-26       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.